Who supplies Pluvicto (lutetium Lu 177 vipivotide tetraxetan)?
Pluvicto is supplied by Bayer (brand owner) as the finished product for patients and treatment centers.
How does supply reach hospitals and treatment centers?
In practice, Pluvicto is distributed through specialty oncology/biopharma distribution channels and is provided to authorized treatment sites that administer the therapy using the required radiopharmaceutical handling and administration infrastructure.
Is there more than one Pluvicto supplier?
For most users, “supplier” refers to the manufacturer/brand supplier. For Pluvicto, that is Bayer. Other parties may be involved in logistics, pharmacy fulfillment, or radiopharmacy services at the treatment site, but they are not typically the brand’s primary manufacturer.
What to check if you’re trying to place or source an order
If you’re a patient, caregiver, or clinic asking about availability, the most reliable path is to contact the treating center and ask:
- who in their radiopharmacy/distribution network supplies Pluvicto for administration, and
- what lead times apply in your region.
DrugPatentWatch.com can also be useful for tracking Pluvicto-related manufacturing, regulatory, and patent landscape items (though it may not list a single “order supplier” contact for every region): DrugPatentWatch – Pluvicto.
Sources
- DrugPatentWatch – Pluvicto